7月6日，Moderna盘中上涨5.13%，报83.85美元/股，成交额3.48亿美元。
消息面上，公司季节性流感疫苗候选产品mRNA-1010此前获FDA咨询委员会9票赞成、0票反对的一致支持，最终审批结果预计8月5日公布，市场对获批预期持续升温。此外，Arete于6月29日将目标价从185美元大幅上调至433美元，远超市场一致目标价319.37美元。公司6月25日科学日活动首次披露体内CAR-T项目mRNA-6007，计划针对自身免疫疾病明年进入临床，叠加肿瘤疫苗、AI研发平台等多条管线展示，市场对其向平台型生物药企估值切换的预期持续发酵。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.